phase readout
saveNCT06492304: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
COMPLETEDupdated 16d ago
community read0 votes
Sponsor: CRISPR Therapeutics. Phase: PHASE1. Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
view source ↗
comments(0)
5-min edit window · permanent after that